Acasti Pharma Inc. Overview
Pro stress-test →Acasti Pharma is a late-stage biopharmaceutical company that has transitioned from cardiovascular health to focus on rare and orphan diseases. The company is advancing GTX-104, a novel injectable nimodipine formulation targeting aneurysmal subarachnoid hemorrhage (aSAH).
Strategic Profile
Pro stress-test →Following its 2021 merger with Grace Therapeutics, Acasti acquired a robust pipeline of clinical-stage assets designed to improve drug efficacy and safety through innovative delivery methods. The company has completed patient enrollment in its Phase 3 STRIVE-ON safety trial and anticipates an NDA submission to the FDA in H1 2025.
Competitive Landscape
Pro stress-test →The STRIVE-ON trial compares GTX-104 to oral nimodipine in a 1:1 ratio, positioning the injectable formulation against the current standard-of-care oral therapy. Direct competitors in injectable nimodipine and aSAH treatment include Hospira (nimodipine oral), and other rare disease biotech firms focusing on neurological disorders.
Industry Context
Acasti Pharma Inc. operates in Rare disease biopharmaceuticals.
Key facts
Founded: N/A · Headquarters: Laval, Quebec, Canada · Employees: N/A · Revenue: N/A · Market cap: N/A